Loading clinical trials...
Loading clinical trials...
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Boryung Pharmaceutical Co., Ltd
Collaborators
NCT07348237 · Chronic Kidney Failure, End-Stage Renal Disease, and more
NCT07426380 · Kidney Disease, Renal Insufficiency Chronic, and more
NCT07154901 · Renal Impairment
NCT07551570 · Renal Impairment
NCT07165015 · Renal Impairment, Healthy, and more
Seoul National University Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions